Divi’s Laboratories leans heavily on selling drug ingredients abroad, but growing pressure for countries to make medicines locally and tougher environmental rules could make that model harder to sustain. See why some think slower growth in newer drug technologies and pricing pressure could outweigh the company’s expansion plans and efficiency upgrades.Read more
Divi’s Labs is betting big on new manufacturing capacity and more complex made-to-order drug ingredients as global drugmakers push more work to specialist suppliers. That could deepen customer ties and lift profits over time, but heavy export exposure and tough pricing pressure could still trip the story up.Read more
Divi’s Laboratories could be closer than it looks to landing bigger, higher-value pharma work as new capacity frees up space and clears regulatory checks. The upside leans on growing demand for newer therapies like peptides and the company’s push into cleaner, more efficient manufacturing—but heavy reliance on exports and a narrow customer mix could quickly spoil the story.Read more
No trending discussion available.
Flawless balance sheet with proven track record and pays a dividend.
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
